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U pper urinary tract calculi is a common disorder with a prevalence of 5.2% in the United States 
(between 1988 and 1994) and showing an increasing 
trend all over the world [1].  The patients present with 
varied symptoms,  and the condition may sometimes 
prove fatal [2 , 3].  Once patients are diagnosed with 
upper urinary tract calculi,  urologists determine the 
most suitable type of surgical treatment from among 
various modalities,  such as extracorporeal shock wave 
lithotripsy (SWL),  ureteroscopic lithotripsy (URSL),  
and percutaneous nephrolithotomy (PCNL),  based on 
the size and localization of the calculus in the urinary 
system [4].  In Japan,  about 60% of the patients with 
upper urinary tract calculi were treated surgically in 
2015,  and 60% and 39% of these patients underwent 
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In this retrospective single-center cohort study,  we investigated the impact of preoperative use of an alpha-1 
adrenergic receptor (AR) blocker on the outcome of single-session extracorporeal shock wave lithotripsy (SWL) 
in 193 male patients who underwent SWL for a single ureteral calculus between 2006 and 2016.  We reviewed 
their medical records to obtain the data on the preoperative use of alpha-1 AR blockers.  The primary outcome 
was treatment success after single-session SWL.  We performed a multivariable logistic regression analysis 
adjusting for clinically important confounders to examine the association between preoperative use of alpha-1 
AR blockers and the treatment success of SWL.  Among the 193 patients,  15 (7.8%) were taking an alpha-1 AR 
blocker preoperatively.  A multivariable analysis showed that preoperative use of an alpha-1 AR blocker was a 
significant negative predictor for treatment success of SWL (adjusted odds ratio 0.17; 95% confidence inter-
vals,  0.04-0.74).  Our findings suggest that the preoperative use of an alpha-1 AR blocker was a negative predic-
tor of treatment success of SWL in male patients with a single ureteral calculus.  Clinicians should pay more 
attention to the preoperative drug use in determining an appropriate stone therapy modality.
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SWL and URSL or PCNL,  respectively [5].  Of the 
aforementioned treatments,  SWL is a good alternative 
modality that may have a clinical advantage over URSL 
in patients with solitary upper urinary tract calculi 
≤ 20 mm [4].  The guidelines issued by the European 
Association of Urology (EAU) [4] and American Uro-
log ical Association (AUA)/Endourological Society 
(https://www.auanet.org/guidelines/kidney-stones- 
surgical-management-guideline) have provided a grade 
B recommendation for both SWL and endourology 
(URSL) in the management of solitary non-lower pole 
calculi ≤ 20 mm in size.
Some meta-analyses have reported the beneficial 
effects of alpha-1 adrenergic receptor (AR) blockers,  
which could cause an earlier expulsion of the stone and 
decrease the requirement for analgesics following SWL 
for ureteral calculi [6 , 7].  The current EAU guidelines 
also recommend postoperative medical expulsive ther-
apy (MET) with alpha-1 AR blockers after SWL in cases 
of residual fragments [4].  On the other hand,  alpha-1 
AR blockers are prescribed for benign prostatic hyper-
plasia (BPH) as well as for MET in men in clinical prac-
tice.  Only one study has revealed beneficial SWL out-
comes with preoperative administration of alpha-1 AR 
blockers for BPH [8].  However,  the effects of preoper-
ative alpha-1 AR blockers in patients who failed MET 
and underwent subsequent SWL is still unknown.  
Therefore,  in this study,  we aimed to characterize the 
preoperative use of alpha-1 AR blockers based on the 
purpose of prescription in male patients who under-
went SWL for ureteral calculi and to evaluate the impact 
of the preoperative administration of alpha-1 AR block-
ers on the outcomes of a subsequent SWL procedure.
Materials and Methods
Study design. We performed a retrospective sin-
gle-center cohort study.
Research setting. The study was conducted at the 
Onomichi Municipal Hospital in Japan.  We included 
patients diagnosed with ureteral calculi from 1 January,  
2006 to 31 December,  2016.
Inclusion and exclusion criteria. We included 
patients who had been diagnosed with solitary upper 
urinary tract calculi on non-contrast computed tomog-
raphy (NCCT) within the study period.  To evaluate the 
association of alpha-1 AR blockers with SWL outcomes,  
only male patients with a solitary ureteral calculus were 
included.  We excluded the patients with multiple cal-
culi,  for whom other surgical modalities such as URSL 
or PCNL were more suitable rather than SWL.  We also 
excluded patients with indwelling ureteral stents,  those 
for whom we did not have follow-up data,  and those 
with missing outcome-data.
Measurement of exposure. For this study,  we 
reviewed the registration forms filled out by the patients 
at the first visit.  The registration forms,  which were 
available in the medical records of patients,  had been 
recorded by well-trained nurses and contained the 
details of every prescription drug the patients were tak-
ing.  We utilized this data to determine whether the 
patient was taking any alpha-1 AR blocker (e.g.,  tamsu-
losin,  naftopidil,  silodosin,  or urapidil) preoperatively.  
It is important to note that none of the patients who 
underwent SWL at Onomichi Municipal Hospital also 
underwent postoperative MET (post-MET) for residual 
fragments.  The patients who were on preoperative 
alpha-1 AR blockers (both for BPH and for preopera-
tive MET (pre-MET)) continued to receive them until 
the completion of SWL.  Pre-MET was performed on 
the same day as the diagnosis of calculus.
Main outcome measures. Our primary outcome 
measure was the proportion of cases in which treatment 
was successfully completed in a single session.  We 
defined a successful treatment as one where the patient 
needed no additional treatment for the ureteral stone 
after completion of a single session of SWL.  We evalu-
ated the outcome of the procedure based on the abdom-
inal X-ray KUB (kidney,  ureter,  and bladder) film 
taken at the patient’s next visit to the outpatient clinic.  If 
the size of the targeted calculus had been < 4 mm,  the 
SWL was deemed successful only when the calculus had 
passed completely and was undetectable on the KUB 
film.  If the size of the targeted calculus had been 
≥ 4 mm,  the procedure was labelled successful either if 
the calculus had completely passed and was undetect-
able on KUB,  or if the residual renal fragments after the 
SWL were determined to be clinically insignificant 
residual fragments (CIRF),  which were defined as frag-
ments < 4 mm [9].  Also,  we defined patients who 
required further treatment with modalities such as 
URSL or PCNL (instead of a second session of SWL) as 
treatment failures (NOT successful treatment).
SWL method. When the calculus did not pass 
spontaneously in four weeks,  regardless of preoperative 
administration of an alpha-1 AR blocker,  the SWL was 
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performed with the Dornier Lithotripter D (Dornier 
MedTech,  Wessling,  Germany) at the hospital.  All 
patients were administered transrectal diclofenac as an 
analgesic prior to the procedure.  For targeting upper 
ureteric calculi,  patients were placed in the supine posi-
tion.  For targeting mid-to-lower ureteric calculi,  
patients were placed in the prone position.  The shock 
waves were applied at a rate of 60 per minute.  The shock 
wave energy was gradually increased according to 
patient tolerance.  The maximum allowable number of 
3000 shocks was administered to almost all the patients.  
The first postoperative follow-up was conducted within 
1 month.  Statistical significance was set at p < 0.05.
Data collection. We collated the relevant data 
from the patients’ medical records.  A standardized pro-
tocol was formulated to collect the data on exposure 
and outcome.  The protocol provided instruction on 
how to measure exposure and outcome in each patient.
Statistical analysis. We analyzed the group-wise 
patient demographics of those who were receiving 
alpha-1 AR blockers and those who were not,  using the 
Wilcoxon rank sum test for the continuous variables 
and the Fisher’s exact test for the categorical variables.  
To evaluate the effectiveness of alpha-1 AR blockers,  we 
mainly applied a multivariable logistic regression analy-
sis.  We selected 5 variables (age,  location of the calcu-
lus,  stone length,  mean stone density (MSD),  and 
skin-to-stone distance (SSD)) as the most important 
confounders,  based on published guidelines [4].  The 
selected confounders were converted to dichotomous 
variables,  with reference to social factors,  anatomical 
factors,  and previous studies: age (cut-off value: 65 
years),  localization of the calculus (upper or mid-to-
lower ureter),  stone length (cut-off value: 5 mm) [10],  
MSD (cut-off value: 600 Hounsfield units (HU)) [11],  
and skin-to-stone distance (cut-off value: 120 mm) 
[11].  We also included information on whether the 
administered alpha-1 AR blocker had effectively served 
the purpose for which it had been prescribed.  We per-
formed an additional analysis of the reasons for which 
the alpha-1 AR blockers were prescribed and also car-
ried out a multivariable logistic regression analysis of 
the dichotomously classified confounders to estimate 
their influence on the outcome of the SWL.  Thus,  we 
performed a complete-case analysis.  The data were 
analyzed using STATA ver. 15.1 (Stata Corp.,  College 
Station,  TX,  USA).
Ethical considerations. The study was approved 
by the Institutional Review Board of the hospital.  The 
approval number was 17-23.  The data were scrubbed of 
all identifying markers and anonymized before the sta-
tistical analysis.  This is a retrospective observational 
study,  and therefore written informed consent was not 
required.
Results
A flowchart with study participant information is 
presented in Fig. 1.  We reviewed the medical records of 
all the patients who underwent SWL at the hospital 
between January 2006 and December 2016 and found 
that 193 patients were eligible to participate.  Of these,  
15 patients (7.8%) had been on some alpha-1 AR 
blocker before the procedure.  Table 1 shows the char-
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???? ?　 Flow-diagram of this study.  A total of 415 patients underwent SWL in the hospital.  Of these,  female patients,  patients with 
renal,  lower calyceal or multiple calculi,  patients with indwelling ureteral stents,  and patients lost-to-follow-up were excluded.  
Consequently,  a total of 193 patients were eligible.
acteristics of the included patients.  The median age was 
57 years and the median BMI was 23.8 kg/m2.  The 
median stone length was 5.6 mm,  and the median MSD 
was 882 HU.  An upper ureteral calculus was diagnosed 
in 135 (69.9%) of the 193 patients.  The patients taking 
alpha-1 AR blockers were found to be older than those 
who were not (62 years vs. 56 years).  In addition,  the 
calculi in the treated group were smaller in diameter 
(4.9 vs. 5.6 mm),  had lower MSD (870 vs. 893.5 HU),  
and had a lower proportion of occurrence in the upper 
ureter (60.0% vs. 67.0%),  respectively.  However,  these 
differences were not found to be statistically significant.  
A successful treatment outcome was seen in 136 
(70.5%) of the 193 patients.  The patients taking the 
alpha-1 AR blockers achieved a significantly lower 
treatment success rate compared to those who were not 
on the medications (46.7% (7 of the 15 patients) vs. 
72.5% (129 of the 178 patients),  p = 0.043).
Table 2 shows the results of the multivariable logistic 
regression analysis estimating the treatment success of a 
single session of SWL.  After making the necessary 
adjustments,  the administration of alpha-1 AR blocker 
was found to be negatively associated with a successful 
treatment outcome (adjusted odds ratio (aOR) 0.17;  
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????? ?　 Multivariable logistic regression analysis estimating treatment success of SWL
aOR 95% CI p-value
Medication of alpha-1 AR blocker (ref. absent)
present 0.17 (0.04-0.74) 0.018
Age (ref. 65 years or more)
less than 65 years 2.16 (1.02-4.60) 0.045
Localization of calculus (ref. mid-to-lower ureter)
upper ureter 1.96 (0.91-4.23) 0.087
Stone length (ref. 5 mm or more)
less than 5 mm 4.51 (1.64-12.42) 0.004
Mean stone density (ref. 600 HU or more)
less than 600 HU 6.82 (1.44-32.20) 0.015
SSD (ref. 120 mm or more)
less than 120 mm 1.11 (0.54-2.28) 0.776
SWL,  shock wave lithotripsy; aOR,  adjusted odds ratio; CI,  confidence interval; AR,  adrenergic receptor; HU,  Hounsfield units; SSD,  
skin-to-stone distance.




alpha-1 AR blocker,  
n=178
Patients with 
alpha-1 AR blocker,  
n=15 p-value
Median [IQR] Median [IQR] Median [IQR]
Age (years) 57 [43-65] 56 [42-65] 62 [51-68] 0.076
BMI (kg/m2) 23.8 [22.2-26.2] 23.9 [22.1-26.2] 23.5 [23.3-25.4] 0.982
History of urolithiasis (present; n,  %) 75 39.7 70＊ 40.2 5 33.3 0.785
Stone length (mm) 5.6 [4.7-7.3] 5.6 [4.7-7.3] 4.9 [4.6-9] 0.613
Mean stone density (HU) 882 [661-1,117] 893.5 [662-1,125.5] 870 [509-1,154] 0.946
SSD (mm) 115.7 [104.7-124] 115.7 [103.7-123.7] 119 [108.7-125] 0.313
Localization of calculus (n,  %) 0.581
Upper ureter 135 69.9 126 70.8 9 60.0
Middle ureter 23 11.9 21 11.8 2 13.3
Lower ureter 35 18.1 31 17.4 4 26.7
AR,  adrenergic receptor; IQR,  interquartile range; BMI,  body mass index; AR,  adrenergic receptor; HU,  Hounsfield units; SSD,  skin-to-
stone distance.
＊Data were missing for 4 of the 178 patients.
95% confidence intervals (CI) 0.04 to 0.74; p = 0.018).  
A significant association of treatment success was also 
seen with physical and anatomical characteristics such 
as age < 65 years (aOR 2.16; 95% CI: 1.02 to 4.60;  
p = 0.045),  stone length < 5 mm (aOR 4.51; 95% CI 
1.64 to 12.42; p = 0.004),  and MSD < 600 HU (OR 
6.82; 95% CI 1.44 to 32.20; p = 0.015).
Table 3 shows the details of the preoperative admin-
istration of alpha-1 AR blockers.  Among the included 
patients,  an alpha-1 AR blocker was preoperatively 
administered for BPH and pre-MET to 7 and 8 patients,  
respectively.  The median durations of administration 
for BPH and pre-MET were 90 days (range: 10 to 1460) 
and 22 days (range: 7 to 90 days),  respectively.  We 
performed an additional analysis using a multivariable 
logistic regression model,  as shown in Table 4,  and the 
results indicated that SWL for pre-MET,  but not SWL 
for BPH,  was a negative predictor for SWL success 
(aOR 0.14,  95% CI 0.02-0.90,  p= 0.038; and aOR 0.23,  
95% CI 0.03-1.97,  p = 0.180,  respectively).
Discussion
In this study,  we described the preoperative use of 
alpha-1 AR blockers and evaluated its association with 
the outcome of a subsequently performed SWL for ure-
teral calculi.  Among the patients,  about 8% were taking 
an alpha-1 AR blocker preoperatively,  with about 4% 
taking an alpha-1 AR blocker for pre-MET.  We achieved 
an overall treatment success rate of 70.1% in our study,  
which was comparable or superior to those attained in 
previous studies (49.6% to 69.9%) [11-13].  In addition,  
we evaluated the association based on the purpose of 
prescription.  We found that the preoperative adminis-
tration of an alpha-1 AR blocker was a statistically sig-
nificant negative predictor for the success of SWL.
Medical expulsive therapy (MET) with alpha-1 AR 
blockers is widely utilized for ureteral stones,  since the 
drugs are localized in the ureter and the blockade of 
alpha-1 AR can relax the ureteric smooth muscle [14].  
The EAU guidelines recommended alpha-1 AR blockers 
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????? ?　 Details of alpha-1 AR blocker use
Purpose of prescription Drugs Dosage n Median administration period (days [range])
For BPH Tamsulosin 0.2 mg 4 90 [10 to 1,460]＊
Silodosin 8 mg 2
Naftopidil 25 mg 1
For pre-MET Tamsulosin 0.2 mg 8 22 [7 to 90]
AR,  adrenergic receptor; BPH,  benign prostatic hypertrophy; pre-MET,  preoperative medical expulsive therapy.
＊Data were missing for 2 of the 7 patients.
????? ?　 Multivariable logistic regression estimating the treatment success of SWL according to the purpose of alpha-1 AR blocker pre-
scription
aOR 95% CI p-value
Medication of alpha-1 AR blocker (ref. absent)
present for BPH 0.23 (0.03-1.97) 0.180
present for pre-MET 0.14 (0.02-0.90) 0.038
Age (ref. 65 years or more)
less than 65 years 2.19 (1.03-4.67) 0.042
Localization of calculus (ref. mid-to-lower ureter)
upper ureter 2.00 (0.92-4.35) 0.082
Stone length (ref. 5 mm or more)
less than 5 mm 4.60 (1.65-12.79) 0.003
Mean stone density (ref. 600 HU or more)
less than 600 HU 6.83 (1.44-32.30) 0.015
SSD (ref. 120 mm or more)
less than 120 mm 1.13 (0.55-2.32) 0.748
SWL,  shock wave lithotripsy; AR,  adrenergic receptor; aOR,  adjusted odds ratio; CI,  confidence interval; BPH,  benign prostatic hyper-
trophy; pre-MET,  preoperative medical expulsive therapy; HU,  Hounsfield units; SSD,  skin-to-stone distance.
for spontaneous passage of both ureteral stones and 
fragments created after SWL [4].  However,  few studies 
have evaluated the effectiveness of preoperative alpha-1 
AR blockers.  Indeed,  to our knowledge there has been 
only one such study which found that preoperative 
alpha-1 AR blockers administered for BPH patients 
improved the stone-free rate after SWL [8].  Moreover,  
the results of this study were not adjusted sufficiently for 
confounding factors (e.g.,  patient age,  stone size,  stone 
location,  number of SWL sessions and shockwaves 
administered per session).  In contrast,  in the present 
analysis we adjusted for sufficient confounding factors 
including NCCT factors,  and we found that the use of 
preoperative alpha-1 AR blockers for BPH had no asso-
ciation with SWL success.  We do not think our findings 
were contrary to those of the aforementioned study,  
since our small sample size may have prevented our 
detecting an association between alpha-1 AR blocker 
use for BPH and SWL success.  On the other hand,  we 
did find a negative association between alpha-1 AR 
blocker use for pre-MET patients and SWL success 
despite our small sample size.  We speculate that 
patients who underwent SWL after pre-MET repre-
sented those who were resistant to SWL,  especially to 
stone passage.  One possible mechanistic explanation is 
that such patients might have decreased ureteral peri-
stalsis due to low expression of alpha-1 AR in their ure-
ters [15],  i.e.,  a MET-resistant condition,  and/or might 
have impacted stones,  for which the effect of SWL is 
limited [16].
Our study has two important strengths.  First,  we 
adjusted for all the known and important confounding 
factors,  including the ones detected on NCCT (patient 
age,  stone length,  localization of the calculus,  MSD,  
and SSD).  In addition,  we had no missing data with 
respect to the confounders due to the rigorous data col-
lection.  Secondly,  we investigated the purpose of the 
prescribed alpha-1 AR blockers in an additional analy-
sis.  To our knowledge,  this is the first study to show 
that alpha-1 AR blockers administered to pre-MET 
patients had a negative impact on the success of a sub-
sequent SWL.  Despite these strengths,  our study also 
has some limitations.  First,  our study is a single-center 
study.  All the patients included were of Asian ethnicity,  
and were from a rural city (Onomichi).  Therefore,  fur-
ther studies will be needed before our findings can be 
generalized to patients of different races or social back-
grounds.  Secondly,  our study cannot help us identify 
the mechanism by which preoperative alpha-1 AR 
blockers decrease the treatment success rate of SWL.  
We need further studies to clarify the mechanism 
underlying our findings.  Thirdly,  although the most 
common waiting period of SWL was four weeks,  we did 
not obtain either the actual waiting period of SWL or 
that of preoperative alpha-1 AR blocker medication.  
Therefore,  we could not clarify the relationship among 
the duration of the waiting period,  pre-MET,  and SWL 
success.  Finally,  the prescribed dose of tamsulosin was 
lower than the standard (0.4 mg/day),  because only 
0.2 mg/day for benign prostatic hyperplasia is provided 
by the Japanese health insurance system.
Our study has a significant clinical implication.  The 
negative influence of the alpha-1 AR blockers is so 
prominent (aOR 0.17 for SWL success) that,  based on 
our findings,  we recommend urologists pay more 
attention to the use of preoperative alpha-1 AR blockers 
when selecting treatment modalities.  Subsequently,  
doing a URSL might be preferable to SWL.  As men-
tioned above,  future studies should focus on verifying 
our findings and discerning the mechanism behind 
them.
In conclusion,  our findings suggest that the preop-
erative use of an alpha-1 AR blocker,  especially for 
MET,  was a negative predictor for treatment success of 
SWL in male patients with a single ureteral calculus.  
Therefore,  urologists should pay more attention to the 
use of alpha-1 AR blockers when selecting a treatment 
modality in patients with a single ureteral calculus.  
Further studies are needed to validate and generalize 
our findings as well as to elucidate the mechanism of 
action of the alpha-1 AR blockers in this scenario.
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